Who are Temozolomide Plus Cisplatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/temozolomide-plus-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Temozolomide Plus Cisplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Temozolomide Plus Cisplatin (Temozolomide Plus Cisplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alkylating agent, platinum-based chemotherapy. Area: Oncology.

phase 3 alkylating agent, platinum-based chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Temozolomide Plus Cisplatin (Temozolomide Plus Cisplatin) — Peking University Cancer Hospital & Institute. Temozolomide is an alkylating agent that works by interfering with DNA replication, while cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting cancer cell growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Temozolomide Plus Cisplatin TARGET	Temozolomide Plus Cisplatin	Peking University Cancer Hospital & Institute	phase 3	alkylating agent, platinum-based chemotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (alkylating agent, platinum-based chemotherapy class)

Peking University Cancer Hospital & Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Temozolomide Plus Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/temozolomide-plus-cisplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab